Treatment of painful diabetic neuropathy: A review of the most efficacious pharmacological treatments

Practical Diabetes International

Volumn 21, Issue 8, 2004, Pages 301-306

  Rogers, L C ^a,b   Alam, U ^b   Malik, Rayaz A ^b   Tesfaye, S ^c  

^a ST VINCENT S HOSPITAL   (United States)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Neuropathy; Pain; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; ISOSORBIDE DINITRATE; MIDOSTAURIN; NICOTINAMIDE; OPIATE; OXCARBAZEPINE; PAROXETINE; PLACEBO; PREGABALIN; RUBOXISTAURIN; SEROTONIN UPTAKE INHIBITOR; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

AGRANULOCYTOSIS; ALGORITHM; ANALGESIA; ANOREXIA; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DIABETIC NEUROPATHY; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EDEMA; FOOD AND DRUG ADMINISTRATION; GAIT; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE; NAUSEA; NERVE DEGENERATION; NEUROPATHIC PAIN; PREVALENCE; QUALITY OF LIFE; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 13344277932     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.703     Document Type: Review

References (54)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998; 21: 1414-1431.
2. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
3. Kumar S, Ashe HA, Parnell LN, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabetic Med 1994; 11: 480-484.
4. Harati Y. Diabetes and the nervous system. Endocrinol Metab Clin North Am 1996; 25: 325-359.
5. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46: S82-S89.
6. Bansal AS, Abdul-Karim B, Malik RA, et al. IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls. J Clin Pathol 1994; 47: 300-302.
7. Malik RA, Veves A, Masson EA, et al. Endoneurial capillary abnormalities in mild human diabetic neuropathy. J Neurol Neurosurg Psych 1992; 55: 557-561.
8. Malik RA, Tesfaye S, Thompson SD, et al. Transperineurial capillary abnormalities in the sural nerve of patients with diabetic neuropathy. Microvasc Res 1994; 48: 236-245.
9. Malik RA. The pathology of human diabetic neuropathy. Diabetes 1997; 46(Suppl 2): S50-S53.
10. Dyck PJ, Zimmerman BR, Vilen TH, et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988; 319: 542-548.
11. Hile C, Veves A. Diabetic neuropathy and microcirculation. Curr Diab Reports 2003; 3: 446-451.
12. Britland ST, Young RJ, Sharma AK, et al. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fibre degeneration and regeneration. Diabetes 1990; 39: 898-908.
13. Boulton AJ. Understanding painful symptomatic diabetic neuropathy. Pract Diabetes Int 2004; 21: 1-5.
14. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-454.
15. Malik RA. Current and future strategies for the management of diabetic neuropathy. Treatments in Endocrinology 2003; 2: 389-400.
16. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000; 55: 915-920.
17. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997; 46: S54-S57.
18. Grant IA, Dyck PJ. Differential diagnosis of diabetic neuropathies. In Diabetic Neuropathy, 2nd edn. Dyck PJ, Thomas PK (eds). Philadelphia: WB Saunders, 1999; 415.
19. DCCT Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568.
20. Morley GK, Mooradian AD, Levine AS, et al. Mechanism of pain in diabetic peripheral neuropathy. Effect of glucose on pain perception in humans. Am J Med 1984; 77: 79-82.
21. Boulton AJM, Malik RA. Diabetic neuropathy. Med Clin North Am 1998; 82(4): 909-929.
22. Oyibo SO, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabetic Med 2002; 19: 870-873.
23. Barbano R, Hart-Gouleau S, Pennella-Vaughan J, et al. Pharmacotherapy of painful diabetic neuropathy. Current Pain Headache Rep 2003; 7: 169-177.
24. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of buproprion SR for the treatment of neuropathic pain. Neurology 2001; 57: 1583-1588.
25. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256.
26. Kvinesdal B, Molin J, Froland A, et al. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251 (13):1727-1730.
27. Max MB, Kishomre-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9.
28. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 520-531.
29. Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther 2001; 23: 520-531.
30. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-1836.
31. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy. Arch Intern Med 1999; 159: 1931-1937.
32. Rothbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-1842.
33. Strojek K, Floter T, Mattern W, et al. Evaluation of flexible and fixed dose of pregabalin in the management of chronic neuropathic pain. Diabetes 2004; 52 (Suppl 2): A25, 105.
34. Bakonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002; 59(Suppl 2): S14-S17.
35. Wilton T. Tegretol in the treatment of diabetic neuropathy. S Aft Med J 1974; 27: 869-872.
36. Rull JA, Quibrera R, Gonzalez-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind crossover study. Diabetologia 1969; 5: 215-220.
37. Gomez-Perez FJ, Choza R, Rios JM, et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525-529.
38. Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1989; 52: 472-476.
39. Farago F. Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur Neurol 1987; 26: 73-83.
40. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage 2003; 25: S31-S35.
41. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-144.
42. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-552.
43. Semenchuk MR, Davis B. Efficacy of sustained-release buproprion in neuropathic pain: an open label study. Clin J Pain 2000; 16: 6-11.
44. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.
45. Ahmad M, Goucke CR. Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 2002; 19: 929-945.
46. Scheffler NM, Sheitel PL, Lipton MN. Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc 1991; 81: 288-293.
47. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin: a multicentre, double-blind, vehicle-controlled study. Arch Intern Med 1991; 151: 2225-2229.
48. Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy: controlled study with long-term follow-up. Diabetes Care 1992; 15: 8-14.
49. Low PA, Opfer-Gehrking TL, Dyck PJ, et al. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal polyneuropathy. Pain 1995; 62: 163-168.
50. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81: 135-145.
51. Yuen KC, Baker NR, Rayman G. Treatment of Chronic Painful Diabetic Neuropathy with Isosorbide Dinitrate Spray: A double-blind placebo-controlled cross-over study. Diabetes Care 2002; 25: 1699-1703.
52. Ametov AS, Barinov A, Dyck PJ, et al; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alphalipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770-776.
53. Litchy W, Dyck PJ, Tesfaye S, et al; The MBBQ Study Group. Diabetic peripheral neuropathy (DPN) assessed by neurological examination (NE) and composite scores (CS) is improved with LY333531 treatment. Diabetes 2002; 45(Suppl 2): 197.
54. Wernicke J, Rosen AS, Lu Y, et al. Superiority of duloxetine over placebo in the treatment of diabetic neuropathic pain demonstrated in two studies. Diabetes 2004; 52(Suppl 2): A24, 104.